Inhibrx Biosciences Inc. (INBX), a clinical-stage biopharmaceutical company, has several high-stakes catalysts on the horizon, making it a stock to watch closely.
The company is focused on developing novel biologic therapeutic candidates for life-threatening conditions based on its proprietary single-domain antibody platform. It has two drug candidates in clinical development - Ozekibart and INBRX-106.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.